Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Blueberry Kush is an indica-dominant hybrid cannabis strain, resulting from a cross between the Blueberry and OG Kush cultivars. It is characterized by a high concentration of delta-9-tetrahydrocannabinol (THC) and a specific terpene profile, including myrcene and caryophyllene, which contribute to its potent sedative and analgesic properties. The drug functions primarily as an agonist at the Cannabinoid receptor 1 (CB1) and Cannabinoid receptor 2 (CB2), modulating the release of various neurotransmitters such as glutamate and GABA. Clinically, it is frequently utilized in medical cannabis frameworks for the management of chronic pain, insomnia, and stress-related disorders due to its ability to induce deep physical relaxation and euphoria.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Blueberry Kush.